More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$303.64B
EPS
7.15
P/E ratio
20.1
Price to sales
4.84
Dividend yield
2.999%
Beta
0.416947
Previous close
$160.20
Today's open
$158.46
Day's range
$158.37 - $160.03
52 week range
$123.24 - $170.46
show more
CEO
Vasant Narasimhan
Employees
75267
Headquarters
Basel,
Exchange
New York Stock Exchange
Shares outstanding
1.91B
Issue type
American Depository Receipt
Healthcare
Pharmaceuticals
NVS Gets FDA Nod for Cosentyx in Adults With Polymyalgia Rheumatica
Novartis wins FDA approval for Cosentyx in adults with PMR, backed by phase III data showing sustained remission and steroid-sparing benefits.
Zacks Investment Research • 4 hours ago

Novartis Cosentyx® becomes first and only FDA-approved anti-IL-17 biologic for people with polymyalgia rheumatica (PMR)
Basel, November 17, 2026 – Novartis today announced that the US Food and Drug Administration (FDA) approved Cosentyx® (secukinumab) 150 mg for the treatment of adult patients with polymyalgia rheumatica (PMR) who have had an inadequate response to corticosteroids or who cannot tolerate corticosteroid taper.¹ Cosentyx is the first and only anti-interleukin-17 (anti-IL-17) biologic approved for people living with PMR, a common inflammatory disease that primarily affects adults over 50, providing a new treatment option beyond long-term steroid use—the current standard of care, which may be associated with significant side effects and risks.¹⁻⁵
GlobeNewsWire • Nov 17, 2026

Novartis' Cosentyx Gets Positive CHMP Opinion for Adolescents With HS
NVS' Cosentyx gains a positive CHMP recommendation for adolescents with moderate to severe HS, potentially expanding treatment options in Europe.
Zacks Investment Research • Nov 16, 2026

Is Novartis (NVS) Outperforming Other Medical Stocks This Year?
Here is how Novartis (NVS) and Alpha Cognition Inc. (ACOG) have performed compared to their sector so far this year.
Zacks Investment Research • Nov 16, 2026

Are You Looking for a Top Momentum Pick? Why Novartis (NVS) is a Great Choice
Does Novartis (NVS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks Investment Research • Nov 12, 2026

A failed trial for a heart drug casts shadow over rivals developing similar therapies
The full data from the closely watched clinical trial showed that the drug had no cardiovascular benefit even though it reduced Lp(a) levels.
Market Watch • Nov 9, 2026

3 Large-Cap Stocks to Watch as Drug & Biotech Sector Rebounds in 2026
In the Large-Cap Pharmaceuticals industry, LLY, NVS and BAYRY are worth watching as the industry shows a strong recovery.
Zacks Investment Research • Nov 9, 2026

Novartis: 3 Key Takeaways for Long-Term Investors
Novartis raised full-year 2026 core operating income guidance after 4% sales growth. Rhapsido peak sales guidance increased to over $4 billion in combined indications.
The Motley Fool • Nov 4, 2026

Novartis heart drug failure leaves doctors seeking evidence for genetic cholesterol target
The recent failure of a Novartis experimental heart drug in a large trial raised questions among cardiologists and investors about the widely held idea tha
Reuters • Nov 2, 2026

6 dividend stocks for investors who want to cut their exposure to the S&P 500
Novartis, Mitsubishi and Canadian Natural are examples of companies in developed markets outside the U.S. that pass screens for high dividend yields and low volatility for prices and earnings.
Market Watch • Nov 2, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Novartis AG commission-free¹. Build wealth for the long term using automated trading and transfers.